**12. References**


http://www.fpg.unc.edu/~publicationsoffice/pdfs/familyneedssurvey.pdf.

Psychosocial Support Needs of Families of Boys with Duchenne Muscular Dystrophy 101

Dawson, S., & Kristjanson, L. J. (2003). Mapping the journey: Family carers' perceptions of

Deber, R. B. (1994). Physicians in health care management: 7. The patient-physician

*Association Journal = Journal De L'association Medicale Canadienne*, *151*(2), 171-6. Deber, R. B. (1994). Physicians in health care management: 8. The patient-physician

Deber, R. B., Kraetschmer, N., & Irvine, J. (1996). What role do patients wish to play in treatment decision making? *Archives of Internal Medicine*, *156*(13), 1414-20. Dempsey, I., Keen, D., Pennell, D., O'Reilly, J., & Neilands, J. (2009). Parent stress, parenting

developmental disability. *Research in Developmental Disabilities*, *30*(3), 558-66. Dunst, C. J., Trivette, C. M., & Hamby, D. W. (2007). Meta-Analysis of family-centered

Emery, A. E. (1991). Population frequencies of inherited neuromuscular diseases--a world

Fairclough, R. J., Bareja, A., & Davies, K. E. (2011). 2010 Joan Mott prize lecture: Progress in therapy for Duchenne muscular dystrophy. *Experimental Physiology.*, 96(11), 1101-13. Finder, J. D., Birnkrant, D., Carl, J., Farber, H. J., Gozal, D., Iannaccone, S. T., . . . American

Firth, M., Gardner-Medwin, D., Hosking, G., & Wilkinson, E. (1983). Interviews with parents

Fitzpatrick, C., Barry, C., & Garvey, C. (1986). Psychiatric disorder among boys with

Fitzpatrick, C., & Barry, C. (1986). Communication within families about Duchenne muscular dystrophy. *Developmental Medicine and Child Neurology*, *28*(5), 596-9. Gibson, B. (2001). Long-Term ventilation for patients with Duchenne muscular dystrophy:

Griggs, R. C., Moxley, R. T., Mendell, J. R., Fenichel, G. M., Brooke, M. H., Pestronk, A., &

Hendriks, A. H., De Moor, J. M., Oud, J. H., & Franken, W. M. (2000). Service needs of

Hoffman, E. P., Brown, R. H., & Kunkel, L. M. (1987). Dystrophin: The protein product of the

neurone disease. *Journal of Palliative Care*, *19*(1), 36-42.

survey. *Neuromuscular Disorders : NMD*, *1*(1), 19-29.

Physicians' beliefs and practices. *Chest*, *119*(3), 940-6.

classes. *Clinical Rehabilitation*, *14*(5), 506-17.

Duchenne dystrophy group. *Archives of Neurology*, *48*(4), 383-8.

Duchenne muscular dystrophy locus. *Cell*, *51*(6), 919-28.

*151*(4), 423-7.

*Research Reviews*, *13*(4), 370-8.

*Care Medicine*, *170*(4), 456-65.

*Child Neurology*, *25*(4), 466-71.

589-95.

issues related to end-stage care of individuals with muscular dystrophy or motor

partnership: Changing roles and the desire for information. *CMAJ : Canadian Medical* 

partnership: Decision making, problem solving and the desire to participate. *CMAJ: Canadian Medical Association Journal = Journal De L'association Medicale Canadienne*,

competence and family-centered support to young children with an intellectual or

helpgiving practices research. *Mental Retardation and Developmental Disabilities* 

Thoracic Society. (2004). Respiratory care of the patient with Duchenne muscular dystrophy: ATS consensus statement. *American Journal of Respiratory and Critical* 

of boys suffering from Duchenne muscular dystrophy. *Developmental Medicine and* 

Duchenne muscular dystrophy. *Developmental Medicine and Child Neurology*, *28*(5),

Miller, J. P. (1991). Prednisone in Duchenne dystrophy. A randomized, controlled trial defining the time course and dose response. Clinical investigation of

parents with motor or multiply disabled children in Dutch therapeutic toddler


Bamm, E. L., & Rosenbaum, P. (2008). Family-Centered theory: Origins, development,

Baskin, B., Banwell, B., Khater, R. A., Hawkins, C., & Ray, P. N. (2009). Becker muscular

Baxter, P. (2006). Treatment of the heart in Duchenne muscular dystrophy. *Developmental* 

Biggar, W. D., Gingras, M., Fehlings, D. L., Harris, V. A., & Steele, C. A. (2001). Deflazacort treatment of Duchenne muscular dystrophy. *The Journal of Pediatrics*, *138*(1), 45-50. Birnkrant, D. J., Bushby, K. M., Amin, R. S., Bach, J. R., Benditt, J. O., Eagle, M., . . . Kravitz,

Bissell, P., May, C. R., & Noyce, P. R. (2004). From compliance to concordance: Barriers to

Boon, H., Verhoef, M., O'Hara, D., & Findlay, B. (2004). From parallel practice to integrative health care: A conceptual framework. *BMC Health Services Research*, *4*(1), 15. Buchanan, D. C., LaBarbera, C. J., Roelofs, R., & Olson, W. (1979). Reactions of families to children with Duchenne muscular dystrophy. *General Hospital Psychiatry*, *1*(3), 262-9. Bushby, K., Muntoni, F., Urtizberea, A., Hughes, R., & Griggs, R. (2004). Report on the 124th

*Physical Medicine and Rehabilitation*, *89*(8), 1618-24.

*Medicine and Child Neurology*, *48*(3), 163.

*Pulmonology*, *45*(8), 739-48.

*Medicine (1982)*, *58*(4), 851-62.

management. *Lancet Neurology*, *9*(1), 77-93.

*Neurology*, *9*(2), 177-89.

*Réadaptation*, *17*(1), 25-37.

Thousand Oaks, CA: Sage.

*19*(3), 189-92.

barriers, and supports to implementation in rehabilitation medicine. *Archives of* 

dystrophy caused by an intronic mutation reducing the efficiency of the splice donor site of intron 26 of the dystrophin gene. *Neuromuscular Disorders: NMD*,

R. M. (2010). The respiratory management of patients with Duchenne muscular dystrophy: A DMD care considerations working group specialty article. *Pediatric* 

accomplishing a re-framed model of health care interactions. *Social Science &* 

ENMC international workshop. Treatment of Duchenne muscular dystrophy; defining the gold standards of management in the use of corticosteroids. 2-4 April 2004, Naarden, the Netherlands. *Neuromuscular Disorders: NMD*, *14*(8-9), 526-34. Bushby, K., Finkel, R., Birnkrant, D. J., Case, L. E., Clemens, P. R., Cripe, L., . . . DMD Care

Considerations Working Group. (2010). Diagnosis and management of Duchenne muscular dystrophy, part 1: Diagnosis, and pharmacological and psychosocial

Considerations Working Group. (2010). Diagnosis and management of Duchenne muscular dystrophy, part 2: Implementation of multidisciplinary care. *Lancet* 

independence scales: The functional independence measure (FIM) and a subjective

Republic of China. *International Journal of Rehabilitation Research. Internationale Zeitschrift Für Rehabilitationsforschung. Revue Internationale De Recherches De* 

muscular dystrophies: Identification of novel aspects of molecular

Bushby, K., Finkel, R., Birnkrant, D. J., Case, L. E., Clemens, P. R., Cripe, L., . . . DMD Care

Chau, N., Daler, S., Andre, J. M., & Patris, A. (1994). Inter-rater agreement of two functional

Chen, J., & Simeonsson, R. J. (1994). Child disability and family needs in the People's

Chen, Y. W., Zhao, P., Borup, R., & Hoffman, E. P. (2000). Expression profiling in the

Coffey, A., Atkinson, P (1996). *Making sense of qualitative data: Complementary Strategies*.

uniform continuous scale. *Disability and Rehabilitation*, *16*(2), 63-71.

pathophysiology. *The Journal of Cell Biology*, *151*(6), 1321-36.


Psychosocial Support Needs of Families of Boys with Duchenne Muscular Dystrophy 103

Morine, K. J., Bish, L. T., Selsby, J. T., Gazzara, J. A., Pendrak, K., Sleeper, M. M., . . .

Moxley, R. T., Ashwal, S., Pandya, S., Connolly, A., Florence, J., Mathews, K., . . . Practice

Msall, M. E., DiGaudio, K., Rogers, B. T., LaForest, S., Catanzaro, N. L., Campbell, J., . . .

Muntoni, F., Bushby, K., & van Ommen, G. (2005). 128Th ENMC international workshop on

Muntoni, F., Bushby, K., & Manzur, A. Y. (2006). Muscular dystrophy campaign funded

Rolland, J. S., & Walsh, F. (2006). Facilitating family resilience with childhood illness and

Rybakova, I. N., Patel, J. R., & Ervasti, J. M. (2000). The dystrophin complex forms a

Schara, U., Mortier, & Mortier, W. (2001). Long-Term steroid therapy in Duchenne muscular

Sheras PL, Abidin RR, Konold TR (1998). *Stress Index for Parents of Adolescents: Professional* 

Schertzer, J. D., van der Poel, C., Shavlakadze, T., Grounds, M. D., & Lynch, G. S. (2008).

Sexton, D., Burrell, B., Thompson, B (1992). Measurement integrity of the Family Needs

Soo, I., Mah, J. K., Barlow, K., Hamiwka, L., & Wirrell, E. (2005). Use of complementary and

*manual*. Odessa, FL: Psychological Assessment Resources, 7-49.

January 2005, London, UK. *Neuromuscular Disorders: NMD*, *16*(3), 210-9. Ottenbacher, K. J., Msall, M. E., Lyon, N. R., Duffy, L. C., Granger, C. V., & Braun, S. (1997).

the Netherlands. *Neuromuscular Disorders : NMD*, *15*(6), 450-7.

*Physical Medicine and Rehabilitation*, *78*(12), 1309-15.

disability. *Current Opinion in Pediatrics*, *18*(5), 527-38.

Survey. *Journal of Early Intervention, 16(4),* 343-352.

of the child neurology society. *Neurology*, *64*(1), 13-20.

*42*(5), 722-30.

*Pediatrics*, *33*(7), 421-30.

*of Cell Biology*, *150*(5), 1209-14.

*Disease*, *2*(4), 179-83.

*294*(1), C161-8.

Sweeney, H. L. (2010). Activin IIB receptor blockade attenuates dystrophic pathology in a mouse model of Duchenne muscular dystrophy. *Muscle & Nerve*,

Committee of the Child Neurology Society. (2005). Practice parameter: Corticosteroid treatment of Duchenne dystrophy: Report of the quality standards subcommittee of the American Academy of Neurology and the practice committee

Duffy, L. C. (1994). The functional independence measure for children (WeeFIM). Conceptual basis and pilot use in children with developmental disabilities. *Clinical* 

'preclinical optimization and phase I/II clinical trials using antisense oligonucleotides in Duchenne muscular dystrophy' 22-24 October 2004, Naarden,

workshop on management of scoliosis in Duchenne muscular dystrophy 24

Interrater agreement and stability of the functional independence measure for children (WeeFIM): Use in children with developmental disabilities. *Archives of* 

mechanically strong link between the sarcolemma and costameric actin. *The Journal* 

dystrophy-positive results versus side effects. *Journal of Clinical Neuromuscular* 

Muscle-Specific overexpression of IGF-I improves E-C coupling in skeletal muscle fibers from dystrophic mdx mice. *American Journal of Physiology. Cell Physiology*,

alternative medical therapies in a pediatric neurology clinic. *The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques*, *32*(4), 524-8. Steele, R. G. (2002). Experiences of families in which a child has a prolonged terminal illness: Modifying factors. *International Journal of Palliative Nursing*, *8*(9), 418-34.


Ivey, S. L., Brown, K. S., Teske, Y., & Silverman, D. (1988). A model for teaching about interdisciplinary practice in health care settings. *Journal of Allied Health*, *17*(3), 189-95. Kinali, M., Main, M., Eliahoo, J., Messina, S., Knight, R. K., Lehovsky, J., . . . Muntoni, F.

Kinali, M., Manzur, A. Y., Mercuri, E., Gibson, B. E., Hartley, L., Simonds, A. K., & Muntoni,

Koenig, M., Monaco, A. P., & Kunkel, L. M. (1988). The complete sequence of dystrophin

Laing, N. G. (1993). Molecular genetics and genetic counselling for Duchenne/Becker

Leibowitz, D., & Dubowitz, V. (1981). Intellect and behaviour in Duchenne muscular dystrophy. *Developmental Medicine and Child Neurology*, *23*(5), 577-90. Mah, J. K., Tough, S., Fung, T., Douglas-England, K., & Verhoef, M. (2006). Adolescent

Mah, J. K., Thannhauser, J. E., Kolski, H., & Dewey, D. (2008). Parental stress and quality of life in children with neuromuscular disease. *Pediatric Neurology*, *39*(2), 102-7. Mah, J. K., Thannhauser, J. E., McNeil, D. A., & Dewey, D. (2008). Being the lifeline: The

Malik, V., Rodino-Klapac, L. R., Viollet, L., Wall, C., King, W., Al-Dahhak, R., . . . Mendell, J.

Markham, L. W., Kinnett, K., Wong, B. L., Woodrow Benson, D., & Cripe, L. H. (2008).

Mendell, J. R., Moxley, R. T., Griggs, R. C., Brooke, M. H., Fenichel, G. M., Miller, J. P., . . .

Moore, M. H., Mah, J. K., & Trute, B. (2009). Family-Centred care and health-related quality

mechanical ventilation. *Neuromuscular Disorders: NMD*, *18*(12), 983-8. Mah, J. K., Selby, K., Campbell, C., Nadeau, A., Tarnopolsky, M., McCormick, A., . . . Yoon,

predicts a rod-shaped cytoskeletal protein. *Cell*, *53*(2), 219-28.

*Publication of the Society for Adolescent Medicine*, *38*(5), 607.e1-7.

*dystrophy.* (pp. p. 37-84). London: Chapman & Hall.

*European Paediatric Neurology Society*, *11*(3), 160-6.

*Ed.)*, *311*(7000), 299-302.

*Neurologiques*, *38*(3), 465-74.

*35*(4), 454-61.

dystrophy. *Annals of Neurology*, *67*(6), 771-80.

*Des Sciences Neurologiques*, *37*(2), 195-205.

(2007). Predictive factors for the development of scoliosis in Duchenne muscular dystrophy. *European Journal of Paediatric Neurology: EJPN : Official Journal of the* 

F. (2006). UK physicians' attitudes and practices in long-term non-invasive ventilation of Duchenne muscular dystrophy. *Pediatric Rehabilitation*, *9*(4), 351-64. Kitzinger, J. (1995). Qualitative research. Introducing focus groups. *BMJ (Clinical Research* 

muscular dystrophy. *In: Partridge TA, editor. Molecular and cell biology of muscular* 

quality of life and satisfaction with care. *The Journal of Adolescent Health : Official* 

parent experience of caring for a child with neuromuscular disease on home

G. (2011). A population-based study of dystrophin mutations in Canada. *The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences* 

R. (2010). Gentamicin-Induced readthrough of stop codons in Duchenne muscular

Corticosteroid treatment retards development of ventricular dysfunction in Duchenne muscular dystrophy. *Neuromuscular Disorders: NMD*, *18*(5), 365-70. McMillan, H. J., Campbell, C., Mah, J. K., & Canadian Paediatric Neuromuscular Group.

(2010). Duchenne muscular dystrophy: Canadian paediatric neuromuscular physicians survey. *The Canadian Journal of Neurological Sciences. Le Journal Canadien* 

Florence, J. (1989). Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy. *The New England Journal of Medicine*, *320*(24), 1592-7.

of life of patients in paediatric neurosciences. *Child: Care, Health and Development*,


**5** 

*Japan* 

**Comparison Between Courses of** 

Toshio Saito1 and Katsunori Tatara2

**Home and Inpatients Mechanical Ventilation** 

**in Patients with Muscular Dystrophy in Japan** 

*1Division of Neurology, National Hospital Organization Toneyama National Hospital 2Division of Pediatrics, National Hospital Organization Tokushima National Hospital* 

In Japan, 27 hospitals specialize in treatment of muscular dystrophy patients, including inpatient care, of which 26 belong to the National Hospital Organization, and the other is the National Center of Neurology and Psychiatry. Since 1999, Japanese muscular dystrophy research groups investigating nervous and mental disorder have been developing a database of cases treated at these 27 institutions. In that regard, we conducted a survey of inpatients and home-mechanical ventilation patients (HMV patients) with muscular dystrophy and other neuromuscular disorders based on data collected by the National

Herein, we examined data obtained in order to evaluate efficacy of mechanical ventilation therapy for HMV patients and mechanical ventilation-dependent inpatients (MV inpatients)

The database includes numbers of inpatients, gender, age, diagnosis, respiratory condition, nutritional state, number of death cases, causes of death, and other relevant findings from data collected annually on October 1 every year since 1999. Additionally we collected the

By using the database and newly collected HMV data, we analyzed the courses of HMV patients group and those of MV inpatients of wards. We compared data of these two groups. Examination points are mechanical ventilation periods, outcome of these two

Objective diseases of this study were muscular dystrophy and spinal muscular atrophy, in particular Duchenne muscular dystrophy and myotonic dystrophy. Amyotrophic lateral

Hospital Organization and National Center of Neurology and Psychiatry.

**1. Introduction** 

with those wards.

**2. Subjects and methods** 

**2.1 Objective diseases** 

sclerosis was not included.

data of HMV patients from 27 institutes for this study.

groups, and caregiver for HMV patients.

